A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older (STRIDE-6).
Scott P, Haranaka M, Choi JH, Stacey H, Dionne M, Greenberg D, Grijalva CG, Orenstein WA, Fernsler D, Gallagher N, Zeng T, Li J, Platt HL; STRIDE-6 Study Group.
Clin Infect Dis. 2024 Dec 17;79(6):1366-1374. doi: 10.1093/cid/ciae383.
Antibody responses to capsular polysaccharide backbone and O-acetate side groups of Streptococcus pneumoniae type 9V in humans and rhesus macaques.
McNeely TB, Staub JM, Rusk CM, Blum MJ, Donnelly JJ.
Infect Immun. 1998 Aug;66(8):3705-10. doi: 10.1128/IAI.66.8.3705-3710.1998.
Lipid Nanoparticle with 1,2-Di-O-octadecenyl-3-trimethylammonium-propane as a Component Lipid Confers Potent Responses of Th1 Cells and Antibody against Vaccine Antigen.
Kawai A, Noda M, Hirata H, Munakata L, Matsuda T, Omata D, Takemura N, Onoe S, Hirose M, Kato T, Saitoh T, Hirai T, Suzuki R, Yoshioka Y.
ACS Nano. 2024 Jul 2;18(26):16589-16609. doi: 10.1021/acsnano.4c00278. Epub 2024 Jun 17.
Antistreptolysin O; a study of this antibody in health and in hemolytic streptococcus respiratory disease in man.
RANTZ LA, RANDALL E, RANTZ HH.
Am J Med. 1948 Jul;5(1):3-23. doi: 10.1016/0002-9343(48)90003-5.
Streptococcus pneumoniae and Its Virulence Factors H(2)O(2) and Pneumolysin Are Potent Mediators of the Acute Chest Syndrome in Sickle Cell Disease.
Gonzales J, Chakraborty T, Romero M, Mraheil MA, Kutlar A, Pace B, Lucas R.
Toxins (Basel). 2021 Feb 17;13(2):157. doi: 10.3390/toxins13020157.
An anti-perfringolysin O monoclonal antibody cross-reactive with streptolysin O protects against streptococcal toxic shock syndrome.
Matsumura T, Nishiyama A, Aiko M, Ainai A, Ikebe T, Chiba J, Ato M, Takahashi Y.
BMC Res Notes. 2020 Sep 5;13(1):419. doi: 10.1186/s13104-020-05264-2.
Post-streptococcal uveitis.
Besada E, Schatz S, Saremi SS.
Optometry. 2000 Apr;71(4):233-8.
How to use antistreptolysin O titre.
Sen ES, Ramanan AV.
Arch Dis Child Educ Pract Ed. 2014 Dec;99(6):231-8. doi: 10.1136/archdischild-2013-304884. Epub 2014 Jan 30.
An mRNA vaccine encoding five conserved Group A Streptococcus antigens.
Harbison-Price N, Sebina I, Bolton RA, Finn M, Cork AJ, Courtney IG, Hancock S, Pelingon R, Richter J, Ericsson O, Green S, Cuellar C, Davis L, Pullinger B, Na J, Elangovan G, De Oliveira DMP, Curren BF, Bickham N, Aguirre M, Dold C, Brouwer S, Plante O, Belz GT, Walker MJ.
Nat Commun. 2025 Jul 1;16(1):5439. doi: 10.1038/s41467-025-60580-0.
Single-chain variable fragment (scFv) targeting streptolysin O controls group A Streptococcus infection.
Aikawa C, Kawashima K, Fukuzaki C, Nakakido M, Murase K, Nozawa T, Tsumoto K, Nakagawa I.
Biochem Biophys Res Commun. 2021 Aug 20;566:177-183. doi: 10.1016/j.bbrc.2021.06.021. Epub 2021 Jun 12.
